Uroplasty to market I-STOP in US:
This article was originally published in Clinica
Executive Summary
Minneapolis, Minnesota-based Uroplasty has secured exclusive US distribution rights to the I-STOP mid-urethral sling for six years, following an agreement with the product's French developer CL Medical (Lyon) to distribute distribution of the I-STOP(TM) in the US. Uroplasty already sells the I-STOP in the UK through its wholly-owned subsidiary based in Reading, Berkshire. According to Uroplasty, the I-STOP is the only monofilament polypropylene tape specifically designed for treating female stress urinary incontinence caused by lack of urethral support (urethral hypermobility).
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.